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the C-terminal region of 
Trypanosoma cruzi MAsps 
is antigenic and secreted via 
exovesicles
Luis Miguel De pablos1,2,*, Isabel María Díaz Lozano1,*, Maria Isabel Jercic3, 
Markela Quinzada4, Maria José Giménez5, eva Calabuig5, Ana Margarita espino6, 
Alejandro Gabriel schijman7, Inés Zulantay8, Werner Apt8 & Antonio osuna1
Trypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical 
disease, endemic to south America and present in non-endemic regions due to human migration. the 
MASP multigene family is specific to T. cruzi, accounting for 6% of the parasite’s genome and plays a 
key role in immune evasion. A common feature of MAsps is the presence of two conserved regions: an 
N-terminal region codifying for signal peptide and a C-terminal (C-term) region, which potentially acts 
as GpI-addition signal peptide. our aim was the analysis of the presence of an immune response against 
the MAsp C-term region. We found that this region is highly conserved, released via exovesicles (eVs) 
and has an associated immune response as revealed by epitope affinity mapping, IFA and inhibition of 
the complement lysis assays. We also demonstrate the presence of a fast IgM response in Balb/c mice 
infected with T. cruzi. our results reveal the presence of non-canonical secreted peptides in eVs, which 
can subsequently be exposed to the immune system with a potential role in evading immune system 
targets in the parasite.
Chagas disease is caused by Trypanosoma cruzi, a flagellated protozoan belonging to the Kinetoplastid order, 
which affects to approximately 7.5 to 10 million people, causing approximately 10,000 deaths every year1,2. This 
disease is a major public concern in endemic areas of Central and South America, but cases can be also found in 
non-endemic countries due to globalization and migratory movements from endemic areas3. The course of the 
disease is marked by two phases: an acute phase with a mortality rate of some 5%, and a chronic phase 5 to 8 weeks 
after the onset of the illness, which remains asymptomatic for a long time; in fact, only 30% of cases ever develop 
any symptoms related to the disease4. The acute phase of the infection in murine experimental models gives rise 
to an enhanced polyclonal humoral response, which is responsible for dysregulating the immune response and 
plays an important part in establishing the parasite within the host in preparation for the chronic phase5,6. This 
hypergammaglobulinemia appears two weeks after the onset of the disease and increases during the following 
two weeks until it reaches its highest level of its specific antibody response, which then persists throughout the 
beginning of the chronic phase (after 60 days), with a rise in IgM, IgG1, IgG3 and IgG2b and a predominance of 
the IgG2a isotype, which increases to ten times its normal value7,8.
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The activation of B cells that comes into play in the course of infection is due to the linear or conformational 
epitopes contained in an antigen, which are capable of giving rise to a humoral response owing to their tendency 
to be exposed to the immune system, their molar ratio and/or their particular conformational organization9,10. 
The high concentration and affinity of antibodies against a particular antigen may also be due to the existence 
of genes that encode proteins with repeated domains, which are defined as possessing one or more copies of an 
amino-acid pattern9,10. This immunodominance is responsible for the response of B lymphocytes to parasites such 
as Plasmodium falciparum11,12, Leishmania infantum13,14 and T. cruzi10,15,16.
Some of the most immunogenic epitopes discovered in T. cruzi are composed of repeated sequences (RSs) 
or sequences repeated in tandem (TRSs)10. These RSs represent a large number of the total number of genes 
belonging to T. cruzi and correspond mainly to its three great gene families: trans-sialidases (TSs), mucins and 
mucin-associated surface proteins (MASPs)17,18. Antigens such as SAPA (Shed Acute Phase Antigen), sequences 
of the conserved C-terminal of TSs or sequences of the central TSSA (Trypomastigote Small Surface Antigen) 
region, belonging to the TcMUCIII mucin family, have been characterized in the TS and mucin families8–21.
Several recent works have demonstrated the presence of TS, mucin and MASP proteins as part of the pro-
tein composition of Exovesicles (EVs) secreted by T. cruzi23–28. EVs are defined as membrane-bound particles 
enclosed by a lipid bilayer and released by cells into extracellular environment27. Depending on the origin, EVs in 
T. cruzi have been classified into two types, the first type are exosome-like EVs (mean size ~70–90 nm), originat-
ing from multivesicular bodies (MVBs) and found to be associated with the flagellar pocket, a structure related 
with the endocytic and exocytic pathways in kinetoplastid parasites; the second type are ectosome-like EVs, 
which are bigger sized structures (mean size ~130–140 nm) that are released after the fusion of multivesicular 
bodies (MVBs) with the plasma membrane27. EVs are known to play a major role in intercellular communication 
and the immune response to parasites27. For instance, the injection of shed vesicles increases the mortality in 
mice infected with T. cruzi due to the production of proinflammatory cytokines, thus playing a pivotal role in the 
pathogenesis of Chagas disease29.
A peptide array screening using up to 110 MASP peptides has confirmed the presence of a humoral response 
against hypervariable regions of these proteins in acutely infected mice30. However, the response against con-
served MASP regions has not been investigated so far. The high levels of expression during the infective stages, 
conservation of the C-terminal (C-term) region of MASPs and its presence in exovesicles render this region sus-
ceptible to be targeted by the immune system, as revealed by the results presented in this study.
Materials and Methods
Human serum samples. All protocols involving human subjects were approved by the Research 
Ethics Committee of the Institute of Public Health and Faculty of Medicine University of Chile, the Gorgas 
Commemorative Institute for Public Health in Panama and La Fe Hospital (Valencia) and University of Granada 
in Spain. All study participants provided written informed consent prior to initiation of study activities and the 
experiments were performed in accordance with the approved guidelines.
The pool of positive sera came from chronic chagasic patients, while negative sera came from healthy controls 
from the Gorgas Commemorative Institute for Public Health in Panama (n = 26). The sera from chagasic patients 
were serum-positive as confirmed by the following immunological test: CHAGAS ELISA IgG + IgM (Vircell) and 
CelQuest Chagas ELISA (ATGen Diagnóstica) and by PCR. Sera from healthy Chilean and Panamanian subjects 
(n = 33) that had proved to be negative with the same analyses were used as a pool of negative controls. The sera 
from the La Fe Hospital (Valencia, Spain) (n = 15) corresponded to an immigrant population from different 
countries, diagnosed also by at least two commercially available immunological methods and confirmed by PCR 
and direct microscopic examination of blood smears. These patients were classified according to their symptoms 
being gastrointestinal, cardiopathic and asymptomatic respectively.
parasites. Epimastigote forms of the CL- Brener (DTU TcVI) and PAN4 (DTU TcI) stocks of T. cruzi31 were 
cultured at 28 °C in MTL medium supplemented with 10% heat-inactivated fetal calf serum (IFCS) as described 
by Ruiz-Perez et al.32. Infective trypomastigote metacyclic forms (M) (70–80% of the cultivated forms after 9 days’ 
culture) were obtained in vitro in modified Grace’s medium and purified by centrifugation in Percoll (GE health-
care) as described by Castanys et al.33.
Cloning and sequencing of the MAsp C-term region. Total RNA from M Pan4 and CL-Brener strains 
was purified using the RNeasy Mini kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthe-
sized using random primers and the iScript cDNA synthesis kit (Bio-Rad Laboratories, Inc). To obtain the differ-
ent sequences corresponding to the conserved C-term region, the MASP-C F 5′ -GGTCTCCCACACCACCTC-3′ 
and MASP C R 5′ -CCACCACCGCAGTAGCAG-3′ primers were used. All the amplification products were puri-
fied and cloned in pGEM-T® Easy Vector (Promega) before being sequenced and analyzed. To test the quality of 
our cDNA samples, total RNA samples were also amplified with the primers described above.
synthetic peptides and bioinformatic analysis. To obtain the consensus sequence of MASP C-term 
region of 200 sequences from T. cruzi genome data base (http://tritrypdb.org/tritrypdb/) we used the Multiple 
Em for Motif Elicitation 4.3.0. (MEME) program (http://meme-suite.org/tools/meme). The analysis was done 
with the maximum number of characters ( = 200 MASP C-term sequences) permitted by the program as input. 
Comparative analysis between the sequenced clones was undertaken using the ClustalW program (http://www.
ebi.ac.uk/Tools/msa/clustalw2/) and the prediction of GPI anchor sites with big-PI program (http://mendel.imp.
ac.at/sat/gpi/gpi_server.html). The obtained C-term consensus sequence was synthesized for a total of six over-
lapping peptides in 12 of their 15 amino-acids, which we refer to as C1, C2, C3, C4, C5 and C6, together with a 
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peptide called C7, corresponding to the C-terminal end of the MASP52 protein, which has amino-acid substitu-
tions in three of its residues34. All the peptides were synthesized by GenScript to > 98% purity (USA, Inc).
Infection of Balb/c mice. Animal experiments were performed in accordance with institutional guide-
lines (Spanish government regulations (Real Decreto RD1201/05)) and European Union guidelines (European 
Directive 2010/63/EU) and were approved by the local authorities (Resolution n° 522 of the Ethics Committee 
of the University of Granada). Three groups of 5 four-week-old, female, Balb/c mice were infected with 1 × 105 
metacyclic trypomastigote forms of T. cruzi, the PAN4 strain, resuspended in PBS and administered by IP injec-
tion in order to assess the humoral response at different times post-infection (pi). After 3 days we proceeded to 
evaluate parasitemia of the trypomastigote forms present in the blood stream by studying smears from 15 µ l blood 
samples taken from the mice by bleeding a section of the tail vein, after fixing with methanol and staining with 
Giemsa.
To obtain serum during the acute phase we bled three of the mice by cardiac puncture on weeks 2, 3 and 4 pi; 
remaining mice were bled after 20 weeks, during the chronic phase of the illness. The sera were centrifuged at 
300 g for 30 min divided into aliquots, and stored at − 20 °C until use.
eLIsA. For the ELISA assays, each well of 96-well Nunc ImmobilizerTM microtitration plates (Thermo sci-
entific) was coated with 1 µ g of one of the peptides diluted in Bicarbonate/carbonate coating buffer (100 mM) 
pH 9.6. The plates were then washed 3 times with PBS-Tween 0.2% (PBS-T) and blocked with skim milk at 2% 
in PBS-T for 1 h at 37 °C. They were subsequently washed 3 times with PBS-T and incubated for 45 min at 37 °C 
with 100 µ l of a 1:200 solution of primary antibody diluted in PBS. Thereafter, the plates were washed 3× with 
PBS-T and then incubated for 30 min at 37 °C with a 1:1000 solution of secondary anti-human IgG antibody 
(Sigma-Aldrich) and/or anti-mouse IgG and IgM (Sigma-Aldrich), all horseradish peroxidase-labeled in 100 µ l of 
PBS. After incubation with the secondary antibodies, the plates were washed 4× and O-phenyl-diaminobenzidine 
plus 30% H2O2 (1 µ l/ml) (Sigma-Aldrich) was added to 0.05 M phosphate-citrate buffer, pH 5.0 as a peroxidase 
substrate before further incubation for 15 min at 27 °C. The reaction was stopped with a solution of 0.1 M 2 N 
H2SO4, and absorption measured at 492 nm in an ELISA Multiskan spectrum reader (Thermo). Sera from healthy 
individuals living in the same areas of Chile and Panama or mouse preinfected sera were used to calculate the 
cut-off value using the formula: median + 3 × SD of the negative samples.
Avidity eLIsA and epitope mapping. To perform the epitope mapping assay and remove low-affinity 
antibodies, KSCN was used as chaotropic agent to increase the stringency of the assay. Briefly, after primary 
antibody incubation and washing 3× with PBS-T, each well was incubated with 0.5 M KSCN for 15 min at 37 °C. 
Then the wells were washed 3 times with PBS-T, following the aforementioned further steps. We calculated the % 
avidity of the pool of positive sera, ((mean OD of KSCN-treated sera/mean OD KSCN-untreated sera) × 100%). 
Indexes above 40% were considered of high avidity30,35.
Isolation of IgGs against the C7 peptide and immunofluorescence assays. IgGs from pooled 
human positive and negative sera were purified according to the manufacturer’s instructions using the protein A 
HP spin trap kit (GE Healthcare).
To purify the specific IgG fraction against the C7 peptide, nitrocellulose strips were coated with the C7 pep-
tide and then immune adsorbed with the IgG purified as described above. The adsorbed antibodies were eluted 
with buffer glycine-HCl 0.1 M (pH 3.5), restoring the neutral pH of the solution by adding 1 M Tris-HCl buffer 
(pH 8.0) supplemented with 0.1% purified bovine serum. The purified IgGs were stored in aliquots at − 80 °C 
until use.
To determine the effectiveness of the process, the eluted IgG fractions were tested by ELISA using Microtiter 
plates (Nunc, Denmark) coated with the C7 peptide (10 µ g/ml) with a titer of at least 1/6400.
Confocal microscopy was performed by using epimastigote forms cultured at the end of the logarithmic 
phase. The parasites were fixed with paraformaldehyde at 3.7% for 15 min at room temperature, washed 3× with 
0.02 M Glycine in PBS, and then permeabilized with 10 mM citric acid, 100 ml H2O, 100 µ l NP-40, pH 6 for 5 min 
at 95 °C. After permeabilization step, the samples were incubated with a 1:500 dilution of either positive and neg-
ative IgGs purified as described above, and the remaining steps were as previously described36.
Cr51 labeled epimastigote forms. The complement lysis assays were carried out in sterile glass tubes in 
which a suspension of the parasite forms was adjusted to 1 × 107 epimastigote forms/ml, the medium was elim-
inated by centrifugation at 1500 g for 15 min and replaced with RPMI (Gibco LTD. Middlesex, England; UK) 
medium with 10% inactivated fetal bovine serum plus 50 mCi/ml of Cr51 (specific activity of 200–900 Ci/mmol) 
(DUPONT, USA).
After incubating for a 2 h, at 28 °C, the parasites were washed by centrifugation, and resuspended in cold non-
radioactive medium, and the parasite pellet resuspended in Veronal Buffer (VB, 10 mM barbital/NaCl 145 mM, 
CaCl 0.15 mM/MgCl 0.5 mM, pH 7.4) (Virion).
To calculate the CH50 (50% cell lysis by complement (CHS)) the 
51Cr labeled epimastigote forms (2.5 × 106 
parasite/ml) were treated with different dilutions of Complement (CHS) (Sigma-Aldrich) (1:200, 1:100, 1:50 and 
1:25) in Veronal Buffer plus 10% of heat-inactivated (56 °C 30 min) Chagas positive (1:500 by ELISA) human pool 
sera and incubated at 37 °C 1 h. Thereafter, the different tubes were centrifuged at 16000 g for 5 min. The superna-
tant was transferred to medium tubes. Each parasite-containing pellet was treated with 1 ml of SDS 0.1%-NaOH 
1 N and transferred to different measurement tubes. The different samples were suspended in Ultima Gold LC 
Cocktail (Sigma) liquid scintillation medium and the radioactivity of the pellet as well as supernatant were 
determined by a γ -spectrometer (Beckman, LS6000) to calculate the specific release of 51Cr, using the following 
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formulae: %LE = (CPMSbn.ctrl/CPSMSbn.Ctrl + CPMpelletCtrl) × 100; %LSP = (CPMSbn.Prb/CPSMSbn.Prb 
+ CPMpelletPrb) × 100. Where: %LE = spontaneous liberation; %LSP = specific liberation; CPMSbn = CPM in 
supernatant; CPM pellet = CPM in the pellet; Ctrl = control; Prb = problem.
The calculation of the complement DL50 parasite lysis (50 CHS) was obtained by lineal regression with the 
specific release data of the different Complement dilution with the Graph Path InStat version 3.06 software.
Complement inhibition by MAsp C-term peptides. After the determination of the 50 CHS, the labeled 
E -51Cr forms were incubated with 10% of heat- inactivated, different pool of positive human sera from Chagas 
disease patients (1:1500), verified by ELISA, with three different pathologies: gastrointestinal, cardiopathic or 
asymptomatic supplemented with the optimal concentration of CHS (CH50 = 1:18) and 1 µ g/100 µ l of each pep-
tide (C1–C7) at 37 °C for 1 h. As a positive control, we used the pooled sera of Chagas disease patients without 
inactivation, and as negative control the pool of inactivated serum without the additional complement.
At the end of the incubation, the samples were processed and measured as described above. The data of the 
percentage of lysis inhibition was calculated by the formula %IC = (LspC − Lsp/Lsc) × 100, where %IC is the 
percentage of complement inhibition.
EVs purification. For the isolation and purification of EVs from bloodstream tripomastigotes, 5 × 107 par-
asites were incubated for 12 h in free EVs medium (RPMI 1640 supplemented with 10% IFCS, which had previ-
ously been centrifuged at 100000 g for 1 h). Next, the parasites were centrifuged at 3000 g for 15 min to eliminate 
remaining of cells and the supernatants were submitted to a protocol of differential centrifugation as previously 
described37. In brief, cell-free media were centrifuged at 17000 g for 20 min, and the supernatants filtered in a 
0.2 µ m filter (Sartorius Minisart) to eliminate any cell debris. The filtered media were finally ultra-centrifuged at 
100000 g for 1 h. The pellets were re-suspended in PBS, washed 3× in PBS and ultra-centrifuged again at 100000 g 
for 1 h. The pellets from the second ultra-centrifugation were re-suspended in PBS and stored at − 20 °C until 
used. All steps were performed at 4 °C in an ultracentrifuge Avanti® J-30I (Beckman Coulter) with a JA-30.50 Ti 
rotor.
To confirm the presence of exosomes in our samples, the pellet was re-suspended in 0.1 M Tris-HCl pH 7.2 
after the last centrifugation. A drop of the suspension was placed on the surface of a Formvar/Carbon copper grid 
and stained by negative stain with 2% v/v uranyl acetate for direct observation by transmission electron micros-
copy. The diameter of EVs was measured by ImajeJ 1.41 software or by light scattering using the Zetasizer Nano 
range system (Malvern Instruments).
Immuno electron Microscopy (eM). The EVs obtained as described above were fixed with Karnovsky’s 
fixative38 (2.5% (v/v) glutaraldehyde, 2%(v/v) formaldehyde in PBS 1X) 4 h at 4 °C and then dehydrated and 
embedded in LR White resin (Sigma). The ultrathin section on grids was blocked in a solution containing 
1% (w/v) gelatine from cold-water fish skin (SIGMA) prepared in PBS 10 min RT, then, placed on three drops 
of 0.02 M glycine in PBS for 5 min each of them, and finally blocked with 1% albumin from chicken egg white 
(Sigma) for 15 min at RT. The grids were placed in a wet chamber and incubated with 20 µ l of a 1:20 dilution of 
anti C-term MASP and anti-clathrin (SCBT) antibodies for 90 min at RT. To eliminate the unbound antibodies, 
the grids were washed 5× in PBS for 25 min and then immersed in a 1:20 dilution of anti-rat and anti-rabbit 
polyclonal antibodies labeled with 10 and 25 nm gold-particles, respectively. Afterwards, the grids were washed 
4× (5 min each) in PBS followed by washing step of 5 min in distilled water. The samples were finally contrasted 
with 2% (v/v) uranyl acetate solution and the EM observations were carried out with a Zeiss (Libra- 2000) trans-
mission microscope.
statistical analysis. To analyze the humoral response against the peptides in the mice samples we first 
determined the cut-off value via the mean value of the negative controls ± 3× SEM. All statistical calculations 
were made with GraphPad Instat v 3.05 software. For all tests, a P value of < 0.05 was considered significant. The 
data of the absorbance were represented with the Slide Write plus for Windows V 7.0.
Results
MAsp amino-acid sequence analysis. To assess possible differences at the amino-acid level, we amplified 
the MASP C-term region of CL Brener (TcVI) and PAN4 (TcI), two phylogenetically divergent strains of T. cruzi 
isolated in Brazil and Panama, respectively. We sequenced a total of 17 clones of the CL-Brener strain and 23 of 
PAN4 (Supplementary Fig. S1). When analyzed, and similarly to what was observed in T. cruzi mucins20, the 
predicted putative GPI anchor attachment (ω -site) site of the C-term region was aspartic acid (D, aa residue 1) 
in 30/40 sequences, while serine was present (S, residue 3) in 8/40 and glycine (G, residue 2) in 1/40 sequences. 
All sequences showed a high degree of homology from residues 1–11 and from aa 20 to 26–31, with a less con-
served hydrophobic region from aa 12–20 (Fig. 1a). However, substitutions were mostly between aa with a neutral 
charge, thus maintaining the characteristic hydrophobicity of this region (aa in blue, Fig. 1c). It can be concluded 
that the C-term region was very similar at the amino-acid level and its physico-chemical characteristics highly 
conserved in all the clones analyzed.
MAsp C-term region localization in exovesicles. Electron microscopic analysis of isolated EVs of 
human infective trypomastigote forms revealed a spherical shape, some as cup-shaped membrane encapsulated 
particles with a size varying from ~90 to 300 nm with a mean of 154.30 nm ± 7.58 nm (although differences may 
correspond to the sagittal cut of the samples). Using immunogold labeling, specific antibodies against the MASP 
C-terminal region showed the presence of MASP proteins bearing the C-term peptide on the EVs (Fig. 2a). After 
analyzing all EVs, the number of EVs containing the MASP C-term region was ~7% with a mean/average of 
1.6 ± 0.8 marks per EVs, whereas clathrin (EVs putative marker) was located in ~30% of the EV population 
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having 1± 0.2 marks per EV (Fig. 2b). The fact that MASP proteins were located in a subpopulation of EVs 
reflects the different protein cargo of the secreted particles by the parasites. To further confirm the presence of 
MASP proteins bearing the C-term in EVs, we performed western blots using antibodies against this conserved 
region in samples of trypomastigote EVs. The size pattern of proteins recognized ranged from ~75 to 25 kDa 
(with the exception of a band of ~170 kDa), which is within the predicted size range for proteins belonging to the 
MASP family.
Humoral response to the C-term region of MAsp proteins. Having demonstrated the presence of 
MASP C-term in EVs, the associated humoral response to this region was investigated in different samples of 
chagasic patients. We first searched for possible differences in the recognition of this region (30 aa long) by syn-
thesizing 6 overlapping peptides (C1–C6) corresponding to the consensus sequence of the MASP C-term region. 
Besides, we also analyzed the C-term region of the MASP52 protein (peptide C7), which we had characterized 
in a previous study34 and found to have three substitutions in the consensus sequence: Leu-Leu-Val instead of 
Phe-Phe-Phe at positions 16–18. Hence, peptide C7 served as a control to ascertain whether amino-acid substi-
tutions with the same polarity entailed changes in the humoral response (Fig. 3a).
Tests on the 7 peptides against a pool of sera from patients with chronic Chagas disease proved positive for all 
the peptides (Fig. 3b). In order to rule out low affinity antibodies, we characterized the affinity of the antibodies in 
the same sera for the different peptides. Peptide C5 showed an affinity of over 60%, while C2, C3 and C7 affinities 
fell within 40–60%, and C1 and C4 were the peptides with lowest affinities (below 40%) (Fig. 3b, bottom panel). 
These results shown that most of the C-term region has specific antibody recognition. It should be kept in mind 
that protein C7, which has three amino-acid substitutions for amino acids with the same charge, maintains an 
associated humoral response.
To confirm the presence of a humoral response not only against linear synthetic peptides but also to confor-
mational epitopes in the MASP C-term region in T. cruzi, we performed an IFA assay using the IgG fraction of 
Figure 1. Analysis of the expressed MASP C-terminal amino-acid sequences.  (a) Agarose gel (2%) of the 
amplicons of the MASP C-terminal region (94-88 bp) using cDNA from the CL-Brener and PAN4 strains as 
a sample and including an mRNA quality control for both strains. (b) Multiple alignment of the sequences 
obtained from the C-terminal region expressed in the PAN4 (23 clones) and CL-Brener (17 clones) strains. 
Residues showing 100% conservation are in black and those showing > 80% are in grey. (c) The graph (blue 
lines) represents a Kyte-Doolitle hydrophaty plot of a prototypical MASP sequence schematized below it. The 
amino-acid frequencies of the C-terminal end of the MASPs expressed by both strains were elucidated by 
MEME (see material and methods) and are represented at the bottom.
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pooled negative and positive sera (the same as above) adsorbed against the C7 peptide. The IFA assay showed 
that the positive-pool sample contained antibodies highly specific to the C7 peptide, not cross-reacting with the 
negative control (Fig. 3c). Nevertheless, it has to be kept in mind that the antibodies that recognize peptide C7 in 
the positive sample may also recognize any other MASP proteins due to high levels of homology of this peptide 
with other members of the family. Hence, the recognition pattern would probably be due to a set of MASP pro-
teins rather than an individual protein. It is noteworthy noting that the MASP C-term region was mainly located 
in small rounded foci close to the kinetoplast in metacyclic trypomastigotes (Fig. 3d), which is in accordance with 
the presence of this region in EVs (Fig. 2a).
We also used the panel of peptides to test the inhibition of the complement activity primed by the presence 
of specific lytic antibodies against the MASP C-term region in pools of sera from patients with different pathol-
ogies (gastrointestinal, cardiopathic or asymptomatic). The Ca2+ independent inhibition is due to the ability to 
sequester specific antibodies and compete with antigens present on the surface of labeled epimastigotes, where 
the complement acts. All in all, we found an inhibition of the lytic activity for most of the peptides and sera, 
with an increased action for the sera from patients with gastrointestinal pathologies and a decrease for sera from 
asymptomatic patients (Fig. 4). Similarly to the affinity assay, the peptide C5 showed the highest percentages of 
inhibition, with the exception of gastrointestinal sera in which C7 was the most effective peptide blocking the 
action of lytic antibodies (Fig. 4). When the individual antibody response for the same sera was tested against the 
peptides, all of them were positive (Fig. 5). However, the values obtained for the peptides were lower compared 
to the control using total lysates of the parasites, which indicates that the response to the C-term region of is just 
a fraction of the total T. cruzi humoral response.
Humoral response to the C-term region of MAsp proteins in infected mice. On determining the 
level of parasitemia in the blood of Balb/c mice infected with T. cruzi (CL-Brener), two distinct peaks for para-
sitemia during the course of the acute phase were obtained on days 12 and 22 pi, which is typical of infection with 
this strain (Fig. 6a). Parasitemia diminished subsequently until becoming imperceptible after the day 30 onwards.
When we analyzed the IgM response, we observed an early positive response from week 2 pi, which contin-
ued to be high until 20 weeks pi for all the peptides assayed (Fig. 6b). On the other hand, the IgG response only 
showed a positive signal for all peptides after 20 weeks pi (Fig. 6c), the titers against IgG always being lower than 
those in response to IgM.
The humoral response observed was not responsible for any significant differences among peptides C1 to C6, 
which make up the C-term consensus sequence, or with regard to C7, which, as mentioned above, contains three 
amino-acid substitutions, although the highest IgG response found was for the C5 peptide.
Discussion
Much of the genome of T. cruzi is composed of repeated elements, among which the following multigene surface 
families are found: TS, mucin, MASP, dispersed gene family-1, gp63, TcTSAV or TcSMP18,39–41. The antigenicity 
of proteins belonging to the TS and mucin families has been previously described, and recent reports showed that 
peptides from the hypervariable MASP region could elicit IgM and IgG responses in experimental infections30. 
Figure 2. Trypomastigote Exovesicles (EVs) cargo MASP C-term region.  (a) Immunogold labeling using 
antibodies against the MASP C-term region. White arrows: Non labeled EVs. Black arrows : labeled EVs (b). 
Quantification of EVs labelling. Bar graphs are representative of at least 100 EVs. (c). Western blot of protein 
extracted from EVs using antibodies against MASP C-term region.
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This, together with the increase in its expression during the infective forms of the life cycle of the parasite, the 
high number of transcripts (1.8–2.8% of the cell total) found in the trypomastigote form, and the location of 
Figure 3. Mapping the affinity of the epitopes in the C-term region of MASP proteins.  (a) Sequence of 
overlapping amino acids used in this study and Kyte-Doolitle hydrophaty plot (bottom graph) of the consensus 
C-term MASP region (b). Mapping of the affinity of the epitopes for a pool of sera from patients suffering from 
chronic Chagas disease. The cut-off value (top graph, tranversal black lines) was calculated using a pool of 
negative sera from Panama using the following formula: Mean + 3 × SD pool of negative samples. Peptides with 
affinity levels (dashed lines) > 40% and < 60% were considered of medium affinity and > 60% of high affinity. 
P values of < 0.001 (*** ) (bottom graph) were considered as extremely significant. (c) IFA assay using a Pool 
of positive (left) or negative (control, right) sera adsorbed against the C7 peptide. (d) Location of the MASP 
C-term region in selected metacyclic trypomastigotes (labeled as “M”). “N” indicates the nucleus and “K” the 
kinetoplast. The white arrows represent the location of MASP C-term in vesicles.
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many of its members in the outside of the parasite membrane34, make MASP proteins a likely target for the mam-
mal host’s immune system, as has recently been demonstrated30. Due to the absence of any defined pattern in the 
hypervariable region of these proteins, we decided to analyze the humoral response against the C-term region of 
the MASP family, a commonly repeated motif that potentially serves as a signal for the addition of the GPI anchor 
at the endoplasmic reticulum.
Our analysis on the possible amino-acid variations in the C-term region confirms the high degree of conser-
vation of this sequence (Fig. 1), indicating that this region may be extremely important for the functionality of the 
MASP family. It has been suggested that, at nucleotide level, it could be the site for homologous recombination42, 
or that it could direct the addition of the preformed GPI-anchor within the lumen of the  endoplasmic reticulum 
at the protein level43.
Given that this MASP protein region is predicted to be cleavage for the addition of the GPI lipid moiety (poten-
tially not present in mature proteins), we looked for alternative pathways for its exposure to the immune system. 
Recent findings have demonstrated that a large proportion of a parasite secretome is released through EVs, with 
the T. cruzi EV protein composition having been recently described23,27. Our results showed that the C-term 
region is present in a subpopulation of trypomastigote EVs (Figs 2 and 3d), also suggesting that the final exposure 
to the immune system of the MASP C-term region might be mediated via EVs. In this sense, two possible sce-
narios can be outlined: (i) a novel role of GPI signal sequences as transmembrane regions in lipid membranes. As 
mentioned above, the vast majority of mature GPI-anchored proteins lacks its C-terminal hydrophobic segment. 
However, there are examples of this region not being excised and instead providing a transmembrane region 
for mature proteins in human plasma membrane cells, like the Bone Marrow Stromal Cell Antigen 2 (BST-2)44. 
Thus, it is possible that MASP GPI signal sequences function as transmembrane regions in EVs membranes; (ii) 
release of misfolded proteins via EVs. In this case, the high production of GPI-anchored proteins in T. cruzi might 
lead to the generation of toxic by-products retaining the GPI-anchor signal peptide, that has not overcome ER 
quality control45. Without its native fold, the proteins would be loaded into MVBs, being finally released through 
EVs46. This mechanism of cellular homeostasis has been found in neurodegenerative diseases such as Alzheimer’s, 
Huntington’s, Parkinson’s and prion diseases and might be part of the regular functioning of T. cruzi cells and/or 
in response to stresses which would lead to the formation of misfolded proteins45,46.
Together with MASP proteins, recent proteomic analysis of T. cruzi EVs revealed the presence of proteins 
without any canonical secretory signals and diverse functionalities, with the most striking examples in proteins 
related with translation and nucleic acid binding23, such as the ribosomal protein P0, which is also recognized by 
serum of chagasic patients47. In the case of the C-term MASP region, our results using sera from chagasic patients 
revealed the presence of a humoral response against the different overlapping peptides, maintaining 5 out of 7 
peptide affinities above 40% when low affinity antibodies were removed (Fig. 3c). Moreover, the IFA assay against 
the C7 peptide demonstrated that this response is also present for conformational epitopes.
The sequencing of the different isolated C-term clones and western blot analysis of trypomastigote EVs using 
anti-MASP C-term antibodies revealed the simultaneous co-expression of several members of this family in EVs, 
which is in agreement with the high diversity of expression of MASP proteins in T. cruzi48. Thus, we can conclude 
that the humoral response to the C-term region is not due to the expression of individual MASP members but to 
the simultaneous expression of numerous MASP proteins, which in turn allows presumption that the molar ratio 
of the antigen exposed to the immune system is very high.
We also confirmed the presence of an antibody response against the MASP C-term region in chagasic patients 
with different pathologies (gastrointestinal, cardiopathic or asymptomatic). However, complement inhibition 
Figure 4. Complement inhibition by MASP C-terminal peptides.  Cr51 labeled Epimastigote forms were 
treated with 10% heat inactivated sera from chagasic patients diagnosed as gastrointestinal, cardiopathic or 
asymptomatic. After incubation with 1/18 dilution human complement (CH50) and 1 µ g/100 µ l of each peptide 
(C1–C7) at 37 °C for 1 h. Pooled sera from chagasic patients without inactivation was used as positive control 
and a pool of inactivate sera without the supplement of complement as a negative control.The data percentage of 
Cr51 specific release was calculated by the formula %IC = (LspC − Lsp/Lsc) × 100, where %IC is the percentage 
of complement inhibition, Lsp the specific liberation of samples, LspC the specific liberation of positive control 
samples and Lspc the specific liberation on negative control samples.
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assays revealed that the response found was different, being lower in pooled sera with cardiac affections compared 
to the highest inhibitions found for peptides C4–C7 in sera with gastrointestinal pathologies. Previous studies 
using mice infected with bioluminescence parasites of the CL-Brener strain, revealed the gut as the main reservoir 
for the long-term persistence of T. cruzi, with the parasite being cleared or not detected in other tissues like the 
heart49. Additionally, quantification of samples from megaesophagus found that 100% of cases were positive for 
the presence of parasite DNA50. Assuming that gastrointestinal cases could be related to the persistence of focal 
T. cruzi populations in the gut, then the constant release of EVs by those populations might contribute to the 
higher antibody response found in the gastrointestinal cases analyzed. Furthermore, the highest complement 
inhibition corresponds to the peptide C7 which belongs to the C-term region of the MASP52 protein, that was 
Figure 5. ELISA of peptides C1–C7 and parasite lysates (total antigen) using sera from patients infected with  
T. cruzi with different manifestations of the disease (gastrointestinal (a), cardiopathic (b) and asymptomatic 
(c)). All the samples with values for OD 492 nm sample/cut-off above 1 were considered positive. The cut-off 
value was calculated using a pool of negative sera from Panama with the following formula: Mean + 3 × SD pool 
of negative samples.
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previously characterized as part of the MASP protein repertoire expressed by the CL-Brener strain, which sup-
ports the preferential tropism of this strain to the gut as mentioned above34,49.
The significant, unspecific polyclonal response during the acute phase of Chagas disease and the subsequent 
control of the expansion of IgG+ B cells, which are highly activated by the Fas/FasL ligand, has been clearly 
demonstrated by various authors7,8,51. This polyclonal lymphocyte B activation induced by MASP proteins has 
been also demonstrated in peptide arrays in which different IgM and IgG recognition patterns seems to be an 
intrinsic characteristic to the hypervariable region of MASP proteins30. Our study shows that the MASP C-term 
region induced a stronger and earlier (2 weeks pi) response for the IgM than the IgG isotopes (Fig. 5), which 
demonstrates that a very rapid humoral response exists for IgM but an insufficient switching occurs to IgG during 
the development of the disease in Balb/c mice. Similarly, the C-term region of the SAPA antigen (which belongs 
to the TS family of T. cruzi), shows high IgM titers at the acute phase of the disease with a reduction on the anti-
body titers of 40% when disease progresses into its chronic phase52. The low switching capacity of B-cells respond-
ing to the exposed MASP C-term region together with prior polyclonal activation by peptides of hypervariable 
regions of the MASP family of proteins might be part of the parasite’s programmed response to avoid immune 
recognition.
In conclusion, our results demonstrate the presence of the MASP C-terminal region in EVs and the presence 
of humoral response against this region with a very fast IgM response in infected mice. Furthermore, our findings 
suggest that the antigenic cargo of EVs actively released by T. cruzi might act as a countermeasure against the 
immunological host defense and thus as a way to evade the humoral immune response.
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